With over 40 years of experience transforming innovative ventures into market-leading enterprises, Matt Kilpatrick is a proven catalyst for growth across biotechnology, healthcare technology, and emerging technology sectors. As Founder and Principal of ZooZ Capital, he spearheads strategic initiatives that drive commercialisation and innovation, transforming novel ideas into market-ready ventures.
Matt’s hands-on leadership approach combines deep corporate acumen with operational excellence, creating substantial value across diverse commercial environments—from rapid growth phases to complex turnaround situations. He specialises in guiding leadership teams of startups and scale-ups, providing the executive counsel needed to accelerate growth, optimise operations, and navigate complex market challenges.
Throughout his career, Matt has orchestrated high-stakes M&A transactions and capital raising campaigns, consistently securing favourable outcomes and forging strategic partnerships to ensure long-term success. His portfolio includes pioneering companies such as GMDx Genomics (precision medicine), Biosignals Diagnostics (cardiac monitoring technology), and Pointlabs (AI-driven loyalty platforms).
As a specialist generalist, Matt brings a creative and dynamic approach to drive outcomes across the entire business lifecycle—from start-up and commercialisation through to landmark events including IPOs and strategic M&A transactions. His unique ability to combine strategic vision with tactical execution has made him a trusted advisor to ambitious leadership teams seeking to scale their innovations and capture significant market opportunities.